Hearing Loss Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have inherited hearing loss that runs in their family in a specific pattern (called "autosomal dominant"), ideally confirmed by a genetic test
- Family members of someone already enrolled in the trial who are known to have this type of inherited hearing loss
- Family members of someone already enrolled who do not have hearing loss (healthy volunteers)
- Adults who are able to read, understand, and sign a consent form themselves
- Children or young people whose parent or guardian is able to read, understand, and sign a consent form on their behalf
- People between the ages of 3 and 99 years old
Who may not be able to join:
- People whose hearing loss was caused by something other than genetics, such as an infection, a metabolic condition, an immune disorder, or exposure to certain drugs like cisplatin or aminoglycoside antibiotics
- People whose hearing loss is linked to a balance problem in the inner ear that was also caused by a non-genetic reason (confirm with trial site)
- People whose hearing loss is known to be related to a past surgery, such as removal of a type of ear tumour (acoustic neuroma) or a failed ear operation (stapedectomy)
- People who have a cognitive impairment that prevents them from being able to understand and agree to take part in the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Joshua M Levy, M.D., National Institute on Deafness and Other Communication Disorders (NIDCD)
Phone: (227) 215-4574
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Determine if genome editing could be applied to modify mutations in primary or immortalized cultured fibroblasts from patients with non-syndromic autosomal dominant hearing loss.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.